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Abstract
Background: Although the invasive lobular carcinoma (ILC) is the second most frequent histologic subtype in
Western countries, its incidence is much lower in Asia, and its characteristics are less well known.
Methods: We assessed the clinical characteristics and outcomes of 83 Korean patients (2.8%) with ILC for
comparison with 2,833 (97.2%) with the invasive ductal carcinoma (IDC), including 1,088 (37.3%) with the luminal A
subtype (LA-IDC).
Results: The mean age of all patients was 48.2 years, with no significant differences among the groups. Compared
to IDC, ILC showed a larger tumor size (≥T2, 59.8% vs. 38.8%, P = 0.001), a lower histologic grade (HG 1/2, 90.4%
vs. 64.4%, P < 0.001), more frequent estrogen receptor positive (90.4% vs. 64.4%, P < 0.001), progesterone receptor
positive (71.1% vs. 50.1%, P < 0.001) and HER2 negative (97.5% vs. 74.6%, P < 0.001) status, and lower Ki-67
expression (10.3% ± 10.6% vs. 20.6% ± 19.8%, P < 0.001), as well as being more likely to be of the luminal A
subtype (91.4% vs. 51.2%, P < 0.001). Six (7.2%) ILC and 359 (12.7%) IDC patients developed disease recurrence,
with a median follow-up of 56.4 (range 4.9-136.6) months. The outcome of ILC was close to LA-IDC (HR 0.77 for
recurrence, 95% CI 0.31-1.90, P = 0.57; HR 0.75 for death, 95% CI 0.18-3.09, P = 0.70) and significantly better than for
the non-LA-IDC (HR 1.69 for recurrence, 95% CI 1.23-2.33, P = 0.001; HR 1.50 for death, 95% CI 0.97-2.33, P = 0.07).
Conclusions: ILC, a rare histologic type of breast cancer in Korea, has distinctive clinicopathological characteristics
similar to those of LA-IDC.
Background
The invasive lobular carcinoma (ILC), known to be the
second most common histologic subtype of invasive
breast cancer following the invasive ductal carcinoma
(IDC), constitutes 8-14% of all breast cancers in most
Western reports [1-3]. However, in Asia it appears to be
very low, accounting for only 2-4% in Korea [4-6] and
1-4% in Japan [7,8].
Previous studies have demonstrated distinctive clinical
and biologic characteristics for ILC as compared with
IDC. For example, it is more likely to occur in older
patients, be larger in size, be estrogen receptor (ER) and
progesterone receptor (PgR) positive and have low to
absent human epidermal growth factor receptor-2
(HER2) expression [9,10]. Traditionally, both ILC and
IDC subtypes have received the same treatment,
depending on their clinicopathological characteristics,
and the prognosis is reported to be similar [10,11].
Recently, classification of breast cancers by gene expres-
sion profiling into particular subtypes has become estab-
lished [12]. However, in clinical practice, the combination
of expression of hormone receptors and HER2 by immu-
nohistochemistry (IHC) is more commonly used to define
breast cancers into the luminal A (ER
+ or PgR
+,H E R 2
-),
luminal B (ER
+ or PgR
+,H E R 2
+), HER2-overexpressing
(ER
- and PgR
-,H E R 2
+), and triple-negative (TNBC: ER
-,
PgR
-,H E R 2
-) subtypes, which demonstrate major differ-
ences in clinical outcomes, with the luminal A subtype
showing the best prognosis [13,14]. The relative distribu-
tions of these four immunohistochemically defined sub-
types in the lobular lesions have yet to be established in
detail.
The purpose of the current study was to analyze the
characteristics of an ILC series and compare the clinical
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and of the luminal A subtype of IDC (LA-IDC).
Methods
Patients
All patients were treated at the National Cancer Center,
Korea during the years from 2001 to 2008. A total of 83
consecutive cases diagnosed with pure ILC, including
two cases with synchronous bilateral ILC, were enrolled
in the study All ILC cases were classic subtype except
for one case which was pleomorphic type. This particu-
lar case was triple negative by IHC. To compare clinico-
pathological characteristics and prognoses, 2,833
consecutive patients diagnosed with IDC during the
same period were also selected.
Clinicopathological evaluation
We retrospectively evaluated conventional clinicopatho-
logical factors, including treatment modalities (type of
operation, use of chemotherapy, hormone therapy, anti-
HER2 therapy and radiotherapy) and the IHC results for
five biological factors (ER [SP1], Ventana; PgR [1E2],
Ventana; HER2 [polyclonal], DAKO; p53 [Bp53-11],
Ventana; and Ki-67 [MIB-1], DAKO) using paraffin-
embedded tissues according to the reported recommen-
dations for tumor marker prognostic studies (REMARK)
[15]. The pathological tumor stage was assessed accord-
ing to the criteria described in the 6th edition of the
American Joint Committee on Cancer (AJCC) staging
manual [16]. The tumor grade was determined accord-
ing to the Scarff-Bloom-Richardson classification modi-
fied by Elston and Ellis [17].
A cut-off value of 10% of positively stained nuclei was
used to define ER and PgR positivity; HER2 was scored
as 0-3+ by a pathologist (Y. Kwon) according to the
method recommended for the Dako Hercep Test. Cases
with IHC scores of 3+ or 2+ with gene amplification by
fluorescence in situ hybridization (FISH) were consid-
ered positive for HER2. Cells with positive staining for
Ki-67 and p53 were counted and expressed as a percen-
tage. For p53, we scored the lesions as 0-3+ (0, negative;
1+, ≤25%; 2+, 25-50%; 3+, >50%). For the prognosis
comparison, low expression was defined as Ki-67 < 20%
and p53 ≤ 25% (median values for all evaluated tumors).
For the subgroup analysis, the definition of Luminal A
was as follows: positive ER or PgR by IHC, negative
HER2 represented by an IHC score of 0 or 1+, or 2+ if
not amplified by FISH. The HER2 cases of an IHC score
of 2+ but no FISH results were counted as unknowns.
The definitions of the other subtypes were as follows:
Luminal B, ER or PgR positive and HER2 positive; HER2
overexpressing, low ER and PgR scores but HER2 posi-
tive; TNBC, low ER and PgR scores and HER2-negative.
Treatment, including surgery, adjuvant chemo, endo-
crine or anti-HER2 therapy, and radiotherapy, was
applied equally to patients with ILC and IDC, dependent
on the clinicopathological characteristics.
Statistical analysis
The primary endpoints of this study were disease-free
survival (DFS) and overall survival (OS). The DFS period
was defined as the interval from the date of diagnosis to
the date of the first observation of disease recurrence,
either loco-regional recurrence or distant metastasis, or
the last follow-up date without any evidence of recur-
rence. Overall survival was calculated from the date of
primary breast cancer diagnosis to the date of death or
last follow-up.
To compare the clinicopathological characteristics
between pairs of groups, we used the Student’st - t e s t
and the chi-square test. The DFS and OS rates were cal-
culated using the Kaplan-Meier method, and the groups
were compared using the log-rank test. For the multi-
variate analysis, Cox regression analysis was applied. Sta-
tistical analyses were performed using Stata 10.0 for
Windows (Stata Corporation Station, TX, USA).
This study protocol was reviewed and approved by the
Institutional Review Board of the National Cancer Cen-
ter (NCCNCS-10-371), Korea, and it complied with the
recommendations of the Declaration of Helsinki for bio-
medical research involving human subjects. The ethical
review board supported that informed consent was not
required for this study.
Results
Patient characteristics
The clinicopathological characteristics of the 83 ILC
patients and 2,833 IDC patients are summarized in
Table 1. The mean ages were 48.3 years and 48.2 years,
respectively, with no difference in the distributions of
age at diagnosis between ILC and IDC (Figure 1). Two
patients with mixed lobular and ductal cancers were
excluded from the analysis.
Compared to the IDC group, significantly more ILC
patients presented with a low histologic grade (HG)
(HG1 or 2, 90.4% vs. 54.9%, P <0 . 0 0 1 )a n dal a r g e
tumor size (≥T2, 59.8% vs. 38.8%, P = 0.001), although
no difference was noted with respect to nodal involve-
ment (43.9% vs. 41.3%, P = 0.18).
Significantly more tumors were positive for hormone
receptors and had a negative HER2 status in the ILC
group as compared to the IDC group (ER
+, 90.4% vs.
64.4%, P < 0.001; PgR
+,7 1 . 1 %v s .5 0 . 1 % ,P < 0.001; HER2
-,
97.5% vs. 74.6%, P < 0.001), with a greater proportion of
the luminal A subtype in the ILC group (91.4% vs. 51.2%,
P < 0.001). In addition, the mean Ki-67 value was lower in
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Page 2 of 8Table 1 Clinicopathological characteristics of invasive lobular carcinoma, invasive ductal carcinoma, and
luminal A subtype
Characteristic
ILC IDC P LA-IDC P
(N = 83) (N = 2833) (N = 1088)
n%n% n%
Mean age (years) 48.3 ± 8.5 48.2 ± 10.5 0.93 47.9 ± 10.2 0.71
pT T1 33 40.2 1730 61.2 0.001 667 61.4 0.001
T2 45 54.9 986 34.9 373 34.4
T3 4 4.9 89 3.1 37 3.4
T4 0 0 23 0.8 9 0.8
Unknown 1 5 2
pN N0 46 56.1 1639 58.7 0.18 551 51.5 0.25
N1 24 29.3 763 27.3 333 31.2
N2 5 6.1 276 9.9 128 12
N3 7 8.5 116 4.2 57 5.3
Unknown 1 39 19
M M0 83 100 2777 98 0.19 1064 97.8 0.17
M1 0 0 56 2 24 2.2
Stage I 25 30.1 1184 41.9 0.06 426 39.3 0.15
II 44 53 1248 44.2 476 44
III 14 16.9 337 11.9 157 14.5
IV 0 0 56 2 24 2.2
Unknown 0 8 5
HG 1 or 2 75 90.4 1438 54.9 <0.001 576 57.3 <0.001
3 8 9.6 1183 45.1 429 42.7
Unknown 212 83
ER Positive 75 90.4 1825 64.4 <0.001 · · ·
Negative 8 9.6 1008 35.6 · ·
PgR Positive 59 71.1 1420 50.1 <0.001 · · ·
Negative 24 28.9 1413 49.9 · ·
HER2 Negative 79 97.5 1586 74.6 <0.001 · · ·
Positive 2 2.5 540 25.4 · ·
Unknown * 2 707 · ·
Subtype Luminal A 74 91.4 1088 51.2 <0.001 · · ·
Non-LA 7 8.6 1038 48.8 · ·
Unknown 2 707 · ·
p53 0 or 1+ 74 93.7 2146 77.7 0.001 951 89.7 0.26
2+ or 3+ 5 6.3 616 22.3 109 10.3
Unknown 4 71 28
Ki-67 10.3 ± 10.6 20.6 ± 19.8 <0.001 13.5 ± 13.2 0.03
Operation BCS 57 68.7 2109 75.1 0.18 786 73 0.39
Mastectomy 26 31.3 698 24.9 290 27
None 0 0 26 3
Adjuvant therapy
Chemotherapy Yes 68 81.9 2383 84.1 0.59 922 84.7 0.49
No 15 18.1 450 15.9 166 15.3
Hormone therapy Yes 79 95.2 2113 74.6 <0.001 1057 97.2 0.31
No 4 4.8 720 25.4 31 2.8
Anti-HER2 therapy Yes
† 1 1.2 164 5.8 0.08 · · ·
No 82 98.8 2669 94.2 · ·
Radiotherapy Yes 64 77.1 2323 82 0.25 879 80.8 0.41
No 19 22.9 510 18 209 19.2
* Including 2+ for HER2 by immunohistochemistry without FISH.
† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial [25] and 53 patients were
enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial [26].
BCS, breast-conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis;
pT, pathological tumor stage; pN, pathological nodal stage; PgR, progesterone receptor.
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Page 3 of 8the ILC group compared to the IDC group (10.3 ± 10.6%
vs. 20.6 ± 19.8%, P <0 . 0 0 1 ) .
Because 91.4% of ILC were of the luminal A subtype,
we further compared ILC to the 1,088 LA-IDC.
Whereas significant differences between ILC and LA-
IDC were found for size, HG and Ki-67, the rates of
nodal involvement and the expression of p53 were simi-
lar (Table 1).
The treatment modalities in the ILC group were also
comparable to those used in the LA-IDC group. One of
two patients with a HER2 positive tumor among the
ILC group who developed disease recurrence received
anti-HER2 treatment upon recurrence.
Univariate analysis of DFS and OS of ILC compared to IDC
patients
During the median follow-up of 56.4 (range 4.9-136.6)
months, 365 patients experienced disease recurrence
(6/83 ILC vs. 359/2833 IDC, P = 0.18) and 213 patients
died (3/83 ILC vs. 210/2833 IDC, P = 0.28). One ILC
patient experienced local recurrence, one contralateral
breast cancer, and four distant metastasis.
Table 2 shows the results of the univariate analysis of
DFS and OS of the ILC group and of all IDC patients.
Significant prognostic factors for DFS were age at diag-
nosis; tumor size; lymph node involvement; individual
ER, PgR, and HER2 statuses; p53 (0 or 1+ vs. 2+ or 3+);
Ki-67 (cut-off: 20%); the type of operation (breast
conserving surgery [BCS] vs. mastectomy); adjuvant
hormone therapy; and intrinsic subtype (luminal A vs.
non-luminal A). However, there was no significant dif-
ference in the 5-year DFS rate between ILC and all IDC
(91.7% in ILC vs. 87.4% in IDC, P = 0.31).
In the univariate analysis of OS, age, tumor size, nodal
status, distant metastasis at diagnosis, individual ER,
PgR, and HER2 statuses, p53, Ki-67, the type of opera-
tion, adjuvant hormone therapy and intrinsic subtype
were prognostic factors. The 5-year OS rate was
93.6% for the ILC group and 92.5% for the IDC group
(P = 0.38).
In this study, we classified the total 2,916 patients into
ILC and four subtypes of IDC and compared the clinical
outcomes. Figure 2 (a, b) presents the DFS and OS
curves. The prognosis of ILC was similar to that of LA-
IDC and was more favorable than with other subtypes
of IDC; the 5-year DFS rates being 91.7% vs. 89.1% for
LA-IDC, 80.7% for the luminal B subtype of IDC (LB-
IDC), 78.9% for the triple-negative subtype of IDC (TN-
IDC), and 75.9% for the HER2 overexpressing subtype
(P < 0.001). The 5-year OS rates were 93.6%, vs. 93.4%,
92.8%, 85.8%, and 83.9%, respectively (P < 0.001).
Multivariate analysis of DFS and OS of ILC compared to
IDC, LA-IDC, and non-LA-IDC
Using the significant variables determined by the uni-
variate analysis, we performed a multivariate analysis for
DFS and OS (Table 3). Patients younger than 35 years
(HR 2.17. 95% CI 1.55-3.02, P < 0.001), with a larger
tumor size (HR 1.85, 95% CI 1.44-2.37, P < 0.001), and
lymph node involvement (HR 2.81, 95% CI 2.15-3.68,
P < 0.001) demonstrated an unfavorable prognosis
(Table 3). Non-LA-IDC (LB-IDC, TN-IDC, and HER2-
overexpressing subtypes) showed a more unfavorable
prognosis compared to LA-IDC (HR 1.69, 95% CI 1.23-
2.33, P = 0.001), but the DFS rates for ILC and LA-IDC
were similar (HR 0.77, 95% CI 0.31-1.90, P = 0.57).
For OS, a young age (HR 1.96. 95% CI 1.27-3.02, P =
0.002), larger tumor size (HR 1.72, 95% CI 1.24-2.40,
P = 0.001), lymph node involvement (HR 2.61, 95%
CI 1.84-3.69, P < 0.001), the presence of distant metas-
tasis at first diagnosis (HR 10.75, 95% CI 6.29-18.37, P <
0.001), p53 overexpression (HR 1.64, 95% CI 1.17-2.31,
P = 0.004), and no hormone therapy (HR 1.81, 95% CI
1.21-2.71, P = 0.004) were identified as independent
factors that were significantly associated with mortality
(Table 3). However, OS did not differ between ILC
and LA-IDC patients (ILC; HR 0.75, 95% CI 1.18-3.09,
P = 0.70).
Figure 2 (c, d) shows the DFS and OS curves adjusted
for other prognostic factors for ILC and IDC subtypes.
T h eD F Sc u r v e sf o rI L Cw e r es i m i l a rt ot h o s ef o rL A -
IDC and were more favorable than those for non-LA-
IDC (P = 0.03). The OS of ILC and LA-IDC was better
than that of non-LA-IDC, but the difference did not
reach statistical significance (P = 0.16).
Discussion
ILC constitutes 2-4% of all breast cancer in Korea, as
presented in the current study, which is much lower
Figure 1 Age distributions of invasive lobular carcinoma (ILC),
invasive ductal carcinoma (IDC), and luminal A subtype of
invasive ductal carcinoma (LA-IDC).
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Page 4 of 8Table 2 Univariate analysis of disease-free survival (DFS) and overall survival (OS) of all patients
Characteristic Patients (n) 5-yr DFS rate (%) P 5-yr OS rate (%) P
Age <35 yrs 226 79.3 <0.001 86.3 <0.001
≥35 yrs 2690 88.2 93.1
pT T1 1763 91.9 <0.001 95.1 <0.001
≥T2 1147 81 89.2
Unknown 6
pN Negative 1685 93.8 <0.001 95.9 <0.001
Positive 1191 81.4 89.6
Unknown 40
M 0 2860 93.9 <0.001
1 56 24.6
Stage I 1209 95.2 <0.001 97.2 <0.001
II 1292 89.4 94.8
III 351 69.2 80.4
IV 56 24.6
Unknown 8
HG 1 or 2 1513 88.7 0.39 93 0.84
3 1191 86.8 92.7
Unknown 212
ER Positive 1900 91.1 <0.001 95.7 <0.001
Negative 1016 80.6 86.8
PgR Positive 1479 92.4 <0.001 96.6 <0.001
Negative 1437 82.7 88.7
HER2 Negative 1665 86.1 <0.001 91.4 0.001
Positive 542 78.4 88.3
Unknown* 709
Subtype Luminal A (LA) 1162 89.3 <0.001 93.9 <0.001
Non-LA 1045 78.5 87.1
Unknown 709
Histological type ILC 83 91.7 0.31 93.6 0.38
IDC 2833 87.4 92.5
p53 0 or 1+ 2220 90.9 <0.001 95.2 <0.001
2+ or 3+ 621 81.8 87.1
Unknown 65
Ki-67 ≤20% 1902 90.1 <0.001 94.4 <0.001
>20% 700 83.4 89.1
Unknown 314
Operation BCS 2166 89.5 <0.001 94.6 <0.001
Mastectomy 724 84.2 88.6
None 27
Adjuvant therapy
Chemotherapy Yes 2318 87.7 0.38 92.6 0.87
No 556 86.6 92.5
Hormone therapy Yes 2192 90.4 <0.001 95.6 <0.001
No 724 78.9 83.9
Anti-HER2 therapy Yes in HER2-positive
† 147 80.7 0.77 93.1 0.48
No in HER2-positive 395 77.4 86.9
HER2-negative or unknown
§ 2374
Radiotherapy Yes 2387 87.8 0.4 92.3 0.38
No 529 86.3 92.9
* Including 2+ for HER2 by immunohistochemistry without FISH.
† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial [25] and 53 patients were
enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial [26].
§ No anti-HER2 therapy due to negative or unknown for HER2 by immunohistochemistry without FISH.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis; pT, pathological tumor stage;
pN, pathological nodal stage; PgR, progesterone receptor.
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Page 5 of 8than the rate observed in most Western reports [1-3].
Although ILC occurs more often in older women in
Western countries [9,10], our series demonstrated that
age distributions were the same as those for overall IDC
at diagnosis. Notably, the peak age of breast cancer
patients in Korea is the late 40 s, which is 10 to 20
years younger than that in Western countries [4].
In the present study, the tumor size of ILC was larger
than that of IDC, as observed in other studies [10,18,19].
Detection may be delayed because ILC is often clinically
Figure 2 Clinical outcomes according to subtypes. Disease-free survival (DFS) curves (a) and overall survival (OS) curves (b) for patients with
invasive lobular carcinoma (ILC) and 4 subtypes of invasive ductal carcinoma (IDC). DFS curves (c) and OS curves (d) for patients with ILC, LA
and non-LA subtypes, adjusting for other prognostic factors in multivariate analysis. Abbreviations: ILC, invasive lobular carcinoma; LA-IDC,
luminal A subtype of invasive ductal carcinoma; LB-IDC, luminal B subtype of invasive ductal carcinoma; TN-IDC, triple-negative subtype of
invasive ductal carcinoma.
Table 3 Multivariate analysis of disease-free survival (DFS) and overall survival (OS)
DFS OS
HR 95% CI P HR 95% CI P
Age (<35 yrs) 2.17 (1.55-3.02) <0.001 1.96 (1.27-3.02) 0.002
pT (≥T2) 1.85 (1.44-2.37) <0.001 1.72 (1.24-2.40) 0.001
pN (positive) 2.81 (2.15-3.68) <0.001 2.61 (1.84-3.69) <0.001
M (1) · · · 10.75 (6.29-18.37) <0.001
Subtype
LA-IDC 1 (ref) 1 (ref)
non LA-IDC 1.69 (1.23-2.33) 0.001 1.5 (0.97-2.33) 0.07
ILC 0.77 (0.31-1.90) 0.57 0.75 (0.18-3.09) 0.7
p53 (>25%) 1.27 (0.96-1.66) 0.09 1.64 (1.17-2.31) 0.004
Ki-67 (≥20%) 1.06 (0.81-1.39) 0.67 1.08 (0.77-1.50) 0.67
Operation (mastectomy) 1.15 (0.89-1.48) 0.29 1.14 (0.82-1.59) 0.44
Hormone therapy (no) 1.19 (0.88-1.62) 0.25 1.81 (1.21-2.71) 0.004
CI, confidence interval; HG, histologic grade; HR, hazard ratio; LA, luminal A; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological
nodal stage
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Page 6 of 8impalpable or mammographically invisible due to a lack of
desmoplasia in the stroma [20]. Despite the larger tumor
size, the rate of lymph node involvement in ILC did not
differ from that in general IDC, which may reflect the slow
growth rate of ILC, and this finding is consistent with
other reports [10,18]. Due to the difficulty associated with
early detection, the larger tumor size in ILC adversely
affected the outcomes of patients with poor DFS in the
present study. We reported that ILC had lower histologic
grade than IDC. Previously, Li et al. analyzed Surveillance,
Epidemiology, and End Results Program data and demon-
strated that ILC showed lower tumor grade than IDC spe-
cifically in 30-49 years old patient group [21]. Although
Rakha et al. reported that histologic grade of ILC provided
a strong predictor of outcome in breast cancer patients
and should be provided routinely in pathology reports, we
did not find such correlation [22].
One of the objectives of the present study was to
characterize more comprehensively the biological phe-
notype of ILC. As previously reported [6,10], the major-
ity of ILC showed ER or PgR positivity and HER2
negativity, which we defined as consistent with the LA-
IDC subtype. Weigelt et al. also showed that most ILC
fall into luminal A molecular subtype, although some
ILC had cluster with either HER2 subtype or apocrine
subtype [23]. Furthermore, ILC demonstrated lower p53
and Ki-67 expression compared to IDC and LA-IDC.
All of these characteristics suggest that ILC likely origi-
nates from more differentiated luminal cells [24].
Previous studies have reported that the prognosis of
ILC patients is similar to that of IDC patients [6,10,18],
as confirmed in the present study. Arpino et al. analyzed
4,140 ILC patients and 45,169 not otherwise specified
IDC patients and reported that the histologic type did
n o ta f f e c tt h ep r o g n o s i sd e s p i t et h ef a v o r a b l eb i o l o g i c a l
phenotype of ILC [10]. However, the outcome of ILC in
t h ep r e s e n ts t u d yw a sc o m p a r a b l et ot h a to fL A - I D C
and significantly better than the outcomes of other,
non-LA-IDC subtypes, when we further analyzed the
prognosis by breast cancer subtype.
This study demonstrated a new aspect of ILC after con-
struing the data including biologic markers other than
general tumor characteristics in the consecutive breast
cancer patients who received consistent therapeutic
approaches at a single center. Similar clinicopathological
characteristics and clinical outcomes between ILC and
LA-IDC were discovered after we further compared ILC
with the four subtypes. To our knowledge, this is the first
report to show such similarities between ILC and LA-IDC.
Conclusions
ILC has distinct clinicopathological characteristics with a
larger tumor at presentation, a lower HG, ER/PgR posi-
tive and HER2 negative status, and low Ki-67
expression, as compared to overall IDC. This study
shows that most ILC are luminal A breast cancer, the
prognosis of ILC is similar to that of LA-IDC, and both
are better than the other subtypes.
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